LUMO — Lumos Pharma Balance Sheet
0.000.00%
- $37.41m
- $23.89m
- $2.05m
Annual balance sheet for Lumos Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 90.5 | 98.7 | 94.8 | 67.4 | 36.1 |
Net Total Receivables | 0.824 | 26.3 | 0.128 | 0.223 | 0.21 |
Prepaid Expenses | |||||
Total Current Assets | 94.4 | 128 | 99.7 | 72 | 40 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.37 | 0.584 | 0.635 | 0.283 | 0.603 |
Long Term Notes Receivable | |||||
Total Assets | 96.8 | 129 | 100 | 72.3 | 40.6 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11.8 | 6.46 | 5.13 | 6.71 | 7.03 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 17.9 | 12.5 | 11.3 | 12.7 | 13.3 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 78.9 | 117 | 89 | 59.6 | 27.3 |
Total Liabilities & Shareholders' Equity | 96.8 | 129 | 100 | 72.3 | 40.6 |
Total Common Shares Outstanding |